ADCT

Adc Therapeutics Sa

• TipRanks·8h ago

  ADC Therapeutics Balances Earnings Gains With Trial Risks

• The Motley Fool·4d ago

  ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript

• Dow Jones·08/17 13:45

  ADC Therapeutics Is Maintained at Buy by Guggenheim

• Dow Jones·08/17 13:45

  ADC Therapeutics Price Target Cut to $5.00/Share From $10.00 by Guggenheim

• Benzinga·08/17 13:41

  Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5

• TipRanks·08/17 11:07

  ADC Therapeutics price target lowered to $5 from $10 at Guggenheim

• TipRanks·08/17 08:04

  ADC Therapeutics reports Q2 adjusted EPS (11c) vs. (25c) last year

• Simply Wall St·08/14 22:44

  ADC Therapeutics (ADCT) Stock Faces LOTIS 5 Doubts Despite Narrower Loss

• TipRanks·08/14 14:25

  RBC Capital Remains a Hold on ADC Therapeutics (ADCT)

• TipRanks·08/13 13:49

  ADC Therapeutics Reports Q2 2026 Results, Reassesses ZYNLONTA Path

• Benzinga·08/13 13:05

  ADC Therapeutics Q2 2026 Earnings Call Transcript

• NASDAQ·08/13 12:50

  ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates

• Seeking Alpha·08/13 11:45

  ADC Therapeutics Non-GAAP EPS of -$0.11, revenue of $19.25M beats by $0.35M

• PR Newswire·08/13 11:30

  ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

• Seeking Alpha·08/12 19:06

  ADC Therapeutics Q2 Earnings Preview